The Top 5 Biosimilars Articles for the Week of April 23
The Center for Biosimilars® recaps the top 5 articles for the week of April 23, 2018.
Transcript:
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of April 23.
Number 5: A recent report demonstrates that there is unequal access to biologics and biosimilars for the treatment of inflammatory bowel disease among nations and regions worldwide.
Number 4: Australia’s Therapeutic Goods Administration has approved Celltrion’s rituximab biosimilar.
Number 3: The FDA’s Arthritis Advisory Committee recommended approval of only 1 of 2 proposed doses of baricitinib, a drug that many believed could compete for market share with Humira.
Number 2: A patient advocacy group is asking the Federal Trade Commission to investigate whether AbbVie’s recent settlements concerning patents on Humira violate the law.
Number 1: The Supreme Court of the United States ruled this week that the inter partes review process, which many biosimilar developers use to challenge patents on biologics, is constitutional.
Finally, last week, our e-newsletter asked whether you think that nurses are getting enough education about biosimilars.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
